Ophthalmologic Manifestations in a Patient with Allopurinol-induced Toxic Epidermal Necrolysis

Authors

Keywords:

toxic epidermal necrolysis, Steven Johnson syndrome, ophthalmologic manifestations

Abstract

Toxic epidermal necrolysis and Stevens Johnson syndrome are clinical variants of the same disease, which is defined as a vesicular erythema multiforme of the skin and other organs. It is considered to be the initial stage of a dermal reaction whose most severe form of presentation is toxic epidermal necrolysis. It manifests as an acute inflammatory systemic reaction involving more than 30% of the body surface. The most important clinical finding is maculopapillary lesions that spread centripetally and evolve into confluent vesicles, usually affecting the oral mucosa, conjunctival and genital area. Stevens Johnson syndrome occasionally evolves to toxic epidermal necrolysis, is characterized by intense pain and loss of the epithelial surface, compromising the vital functions of the organism, causing a hydroelectrolytic imbalance, renal and ocular compromise, a great catabolism and a potential risk of sepsis, being drugs the most frequent etiologic agent. The 50-67 % of patients with toxic epidermal necrolysis present ocular affectations, among the most common are membranous and pseudomembranous conjunctivitis, as well as symblepharon formation. A case of adverse drug reaction is presented in a 49-year-old male patient, with a history of systemic lupus erythematosus, arterial hypertension and hyperuricemia, who was treated at the Clinical-Surgical Hospital Hermanos Ameijeiras for presenting multiform erythematous skin lesions and ophthalmologic manifestations, after having started treatment with allopurinol.

Downloads

Download data is not yet available.

References

1. Paulino Basulto R, García de Varona R, Estremera Morales N, del Sol Serrallonga N. Necrólisis epidérmica tóxica. Presentación de un caso. Arch méd Camagüey. 2005 [acceso 13/05/24];9(1):126-31. Disponible en: https://revistaamc.sld.cu/index.php/amc/article/view/2992

2. Álvarez Espinoza MA, Bastidas Montalvo AM, Lino Gutiérrez CH, Guanotasig Guamba KD. Síndrome de necrólisis epidérmica tóxica y síndrome de Stevens Johnson clínica y tratamiento. Revista polo de conocimiento. 2024;9(9):544-60. DOI:10.23857/pc.v9i9.7949

3. Soto M, Hernández FP. Necrólisis epidérmica toxica: Presentación de un caso. Rev Chil Anest. 2023;52(5):542-4. DOI: 10.25237/revchilanestv52n5-15

4. Necrólisis epidérmica tóxica en paciente inmunodeprimido. Rev Ecuat Cienc Tecnol Innovacion En Salud Publica. 2021:1-5. DOI: 10.31790/inspilip.v4i3.244

5. Arias DA, Londoño PA, López JG, Moreno LH. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica en el Hospital Universitario del Valle “Evaristo García” durante un período de 9 años. Rev Asoc Colomb Dermatol Cirugia Dermatol. 2013;21(3):214-9. DOI: 10.29176/2590843x.256

6. Valdés Mesa S, Planas Pavón M, Benitez Martínez R. Necrólisis tóxica epidérmica: particularidades de su atención. Rev Cub Med Mil. 2007 [acceso 13/05/24];36(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-6557200700300009&Ing=es.

7. Roujeau JC. Epidermal necrolysis (Stevens–Johnson syndrome and toxic epidermal necrolysis): Historical considerations. Dermatol Sin. 2013;31(4):169-74. DOI: 10.1016/j.dsi.2013.09.009

8. Gregory DG. USA: Ophthalmologic evaluation and management of acute Stevens-Johnson syndrome. Front Med. 2021;8. DOI: 10.3389/fmed.2021.670643

9. Tomlins PJ, Parulekar MV, Rauz S. “Triple-TEN” in the treatment of acute ocular complications from toxic epidermal necrolysis. Cornea. 2013;32(3):365-9. DOI: 10.1097/ico.0b013e318243fee3

10. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol. 2007;91(8):1048-53. DOI: 10.1136/bjo.2006.109124

11. Zhang N, Geng X, Liu R, Liu X, Cui H, Dou R, et al. Novel technique for amniotic membrane transplantation for acute Stevens-Johnson syndrome/toxic epidermal necrolysis patients. Heliyon. 2023;9(8):e18853. DOI: 10.1016/j.heliyon.2023.e18853

12. Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema multiforme, Stevens‐Johnson syndrome/toxic epidermal necrolysis–diagnosis and treatment. JDDG. 2020;18(6):547-53. DOI: 10.1111/ddg.14118

13. Correa-Muñoz E, Llano-Naranjo Y, Arias-Uribe J, Gómez-Suárez IC, Llano-Naranjo Y, Donado-Gómez JH. Caracterización de pacientes con enfermedad de ojo seco en una institución de referencia en la ciudad de Medellín, Colombia. Rev Soc Colomb Oftalmol. 2022;54(2). DOI: 10.24875/rsco.m21000016

14. González Santiesteban AG, Larrondo Muguercia HM, Pérez Mesa Y. Necrólisis tóxica epidermica en cuidados intensivos. Rev Cubana med. 2020 [acceso 13/05/24];59(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232020000400012&Ing=es.

15. Plazola Hernández SI, Hernández Martínez N. Uso de membrana amniótica en el manejo oftalmológico agudo de la necrólisis epidérmica tóxica: presentación de caso. Rev Mex Oftalmol. 2016;90(4):200-4. DOI: 10.1016/j.mexoft.2015.06.008

Published

2025-03-19

How to Cite

1.
Sera Herrero K, Florian Estevez A, Pérez Gómez D, Miranda Palacio G, López Rodríguez R. Ophthalmologic Manifestations in a Patient with Allopurinol-induced Toxic Epidermal Necrolysis. Rev Cubana Oftalmol [Internet]. 2025 Mar. 19 [cited 2025 Apr. 1];38. Available from: https://revoftalmologia.sld.cu/index.php/oftalmologia/article/view/1902

Issue

Section

Presentación de casos

Most read articles by the same author(s)

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.